Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors while in the central anxious procedure, conolidine modulates alternate molecular targets. A Science Advances study found that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://walta765hyn5.sasugawiki.com/user